PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial

Novo Nordisk’s investigational interleukin-6 (IL-6) inhibitor ziltivekimab met the primary endpoint in a Phase II trial in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive protein (hsCRP), representing high cardiovascular risk.
The RESCUE trial assessed the effect of once-monthly subcutaneous ziltivekimab on biomarkers of inflammation in patients with advanced CKD and elevated hsCRP.
The Danish pharma company revealed that the trial met its primary endpoint, demonstrating that median levels of hsCRP were significantly reduced with ziltivekimab compared with placebo – 77%, 88% and 92% reduction in those receiving 7.5 mg, 15 mg and 30 mg of ziltivekimab compared with just 4% for placebo.
The amount of participants who achieved both a greater than 50% reduction in hsCRP and had hsCRP levels of less than 2mg/L was also ‘significantly’ higher with ziltivekimab compared to placebo.
“We are very encouraged by these promising Phase II data, which is an important step towards a new potential anti-inflammatory treatment approach for people living with atherosclerotic CVD and CKD,” said Martin Holst Lange, executive vice president for development at Novo Nordisk.
“Based on these results, we are planning to progress ziltivekimab to a large-scale Phase III cardiovascular outcomes trial to further assess its potential, as we continue to advance our commitment in cardiovascular disease,” he added.
Biomarkers for inflammation, such as hsCRP, and chronic inflammation contribute to the development of progression of atherosclerosis – a major cause of cardiovascular disease (CVD).
Atherosclerosis occurs as a result of a build-up of fats, cholesterol and other substances in the artery walls, causing vessel narrowing and reduced blood flow.
Approximately half of all deaths in people with CKD are caused by CVD-related symptoms, suggesting that people living with CKD are more likely to die from CVD than progress to end-stage renal disease.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026